Femoral neck osteopenia in patients with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 93, Issue 9, 1998, Pages 1483-1490

  Pollak, Rivka Dresner ^a   Karmeli, Fanny ^a   Eliakim, Rami ^a   Ackerman, Zvi ^a   Tabb, Kevin ^a   Rachmilewitz, Daniel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; OSTEOCALCIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; COLON CROHN DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FEMUR NECK; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; PRIORITY JOURNAL; SPINE; ULCERATIVE COLITIS;

ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; COLITIS, ULCERATIVE; COLLAGEN; CROHN DISEASE; FEMALE; FEMUR NECK; HUMANS; INTERLEUKIN-6; MALE; OSTEOCALCIN; PARATHYROID HORMONE; SPINE; VITAMIN D;

EID: 0032172870     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.468_q.x     Document Type: Article

References (37)

1. 1. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-5.
2. 2. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396-1403.
3. 3. Clements D, Motley RJ, Evans WD, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055-60.
4. 4. Bjarnason I, Macpherson C, Buxton-Thomas M, et al. Reduced bone mineral density in patients with inflammatory bowel disease. Gut 1997;40:228-33.
5. 5. Bischoff SC, Herrmann A, Goke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997;92:1157-63.
6. 6. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not to disease diagnosis. J Bone Miner Res 1995;10:250-6.
7. 7. Leichtmann G, Bengoa JM, Bolt MJG, et al. Intestinal absorption of calciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. Am J Clin Nutr 1991;54:548-52.
8. 8. Clements D, Compston JE, Evans WD, et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-6.
9. 9. Eriksen EF, Brixen K, Charles P. New markers of bone metabolism: Clinical use in metabolic bone disease. Eur J Endocrinol 1995;132: 251-63.
10. 10. Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinum cross-links of collagen: Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992;3:263-70.
11. 11. Lin CL, Moniz C, Chambers TJ, et al. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996;111: 1263-71.
12. 12. Abitol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108: 417-22.
13. 13. Robinson RJ, Iqbal SJ, Whitaker RP, et al. Rectal steroids suppress bone formation in patients with colitis. Aliment Ther 1997;11:201-4.
14. 14. Silvennoinen J, Risteli L, Karttunen T, et al. Increased degradation of type 1 collagen in patients with inflammatory bowel disease. Gut 1996;38:223-8.
15. 15. Kanis JA, Melton LJ III, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
16. 16. Garnero P, Grimaux M, Demiaux B, et al. Measurement of serum osteocalcin with a human specific two site radioimmunoassay. J Bone Miner Res 1992;7:1389-97.
17. 17. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new radiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
18. 18. Hanson DA, Weis MAE, Bollen A-M, et al. A specific immunoassay for monitoring human bone resorption: Quantitation of type 1 collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7: 1251-8.
19. 19. Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis at diagnosis. Gastroenterol 1994;107:1031-9.
20. 20. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study. Gut 1997;40:313-9.
21. 21. Bross DA, Leichtner AM, Zurakowski D, et al. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J Pediatr Gastroenterol Nutr 1996;23:164-71.
22. 22. Mashida YR, Kurlac L, Gallaghner A, et al. High circulating concentrations of interleukin-6 in active Crohn's disease but not in ulcerative colitis. Gut 1992;32:1531-4.
23. 23. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102:514-9.
24. 24. Schreiber S, Raedler A, Stenson WF, et al. The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am 1992;21:451-502.
25. 25. Ligumsky M, Simon PL, Karmeli F, et al. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 1990;31:686-9.
26. 26. J-M, Wittersheim C, Dumont S, et al. Increased production of tumor necrosis factor-α, interleukin-1, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-9.
27. 27. GD, Interleukin-6: An osteotropic factor? J Bone Miner Res 1992;7: 475-8.
28. 28. Elias JA, Lentz V. IL-I and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. J Immunol 1990;145:161-6.
29. 29. Gowen M, Wood DD, Ihrie EJ, et al. An interleukin-1-like factor stimulates bone resorption in vitro. Nature 1983;306:378-80.
30. 30. Boyce BF, Aufdemorte TB, Garrett, et al. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989;125:1142-50.
31. 31. Kitazawa R, Kimble RB, Vannice JL, et al. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 1994;94:2397-2406.
32. 32. Woodroofe C, Muller W, Ruther U. Longterm consequences of interleukin-6 in transgenic mice. DNA Cell Biol 1992;11:587-92.
33. 33. Felix R, Cecchini MG, Fleish H. Macrophage colony-stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 1990;127:2592-7.
34. 34. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257:88-91.
35. 35. Kania DM, Binkley N, Checovich M, et al. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J Am Geriat Soc 1995;43:236-9.
36. 36. Greenspan SL, Dresner Pollak R, Parker RA, et al. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 1997;60:419-23.
37. 37. Dresner Pollak R, Rosen HN, Clemens JD, et al. Reliability of spot urine collection for measurement of bone resorption by cross-linked N-telopeptide assay in the elderly. J Bone Miner Res 1993;8(suppl): s809.